Inhalation Sciences assignment in the FORMAMP project on antibiotic resistance is extended by 1,2 MSEK.
Antibiotic resistance is one of the most pressing health concerns on the planet. The EU research project FORMAMP is exploring ways of using Antimicrobial Peptides (AMPs) combined with other nanoformulation strategies, to prevent it. Inhalation Sciences has been contracted to carry out an additional series of studies for the project, extending its role and research revenues.
Inhalation Sciences (ISAB) is being contracted to carry out an additional series of studies during 2017 aiming at characterizing silica particles and assess their potential as an inhaled formulation. The extended research will translate to a maximum of approximately SEK 1,2 MSEK in revenues for ISAB.
FORMAMP is a highly innovative project pioneering new ways of using nanotechnology to formulate and deliver AMPs as a therapy. FORMAMP has already used Inhalation Sciences’ in vitro, ex vivo and in vivo research technology in its project.
ISAB CSO Per Gerde says: “This is a very good project for us. We will be able to provide the required inhalation technology entirely from our in-house methods. I think we are one of the few companies in the world who can deliver the quality of data needed here. We are pleased to contribute to this important cross-disciplinary project. Inhalation technology has an important role to play in peptide research and therapies.”
FORMAMP’s Project Coordinator Dr Lovisa Ringstad says: “We are very excited about the findings from ISAB’s studies related to the project, and the fact that the lung distribution can be measured. This knowledge is highly important in order to design formulations so that the actives are delivered to the right place, which is a prerequisite for treating serious lung infections locally. The contribution from ISAB is extremely valuable for the project. We very much look forward to the results from the additional studies that will be done during the final part of the project.”
For more information about Inhalation Sciences please contact: Fredrik Sjövall, CEO Email: email@example.com Phone: +46 (0)70 64 508 75Press release in PDF format